Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    mosaico
Previous Study | Return to List | Next Study

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03964415
Recruitment Status : Not yet recruiting
First Posted : May 27, 2019
Last Update Posted : August 7, 2019
Sponsor:
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.

Brief Summary:
The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection in HIV-1 seronegative cis-gender men and transgender individuals having sex with cis-gender men and/or transgender individuals.

Condition or disease Intervention/treatment Phase
Healthy Biological: Ad26.Mos4.HIV Biological: Clade C and Mosaic gp140 HIV bivalent vaccine Biological: Placebo Phase 3

Detailed Description:
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that, if left untreated, can progress to acquired immunodeficiency syndrome (AIDS), a condition in which the immune system is severely compromised, leading to life-threatening conditions. Ad26.Mos4.HIV is a tetravalent vaccine composed of Ad26.Mos1.Gag-Pol, Ad26.Mos2.Gag-Pol, Ad26.Mos1.Env, and Ad26.Mos2S.Env. Clade C and Mosaic gp140 HIV bivalent vaccine contains: Clade C gp140, HIV-1 Env gp140 of Clade C, Mosaic gp140, HIV-1 Env gp140, and aluminum phosphate adjuvant. Evidences showed that a combination of vaccination with Ad26.Mos.HIV followed by Ad26.Mos.HIV together with Clade C gp140 protein in aluminum phosphate adjuvant led to highest level of protection observed so far with this vaccine concept. Study comprises of a screening period of 45 days, a 12-month vaccination period and a follow-up period of at least 18 months after fourth vaccination (until Month 30) in participants who remain HIV-1 negative or up to 6 months after diagnosis of HIV-1 infection in participants who become HIV-1 infected. Participants who completed their Month 30 visit will be followed for HIV infection, medically-attended adverse event (MAAEs) and serious adverse events until the end of study (Month 30). Primary analysis of vaccine efficacy will evaluate the number of HIV-1 infections in the vaccine group compared to number of HIV-1 infections in the placebo group between Month 7 and Month X (with 24<=X<=30) in per-protocol population.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 3800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
Estimated Study Start Date : September 10, 2019
Estimated Primary Completion Date : January 3, 2023
Estimated Study Completion Date : June 23, 2023


Arm Intervention/treatment
Experimental: Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine
Participants will receive adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) via intramuscular (IM) injection into the deltoid muscle at months 0 (Day 1) and 3 (preferably the deltoid of the non-dominant upper arm) and, Ad26.Mos4.HIV together with Clade C and Mosaic gp140 HIV bivalent vaccine IM into the deltoid muscle at Months 6 and 12 (different deltoid for each injection).
Biological: Ad26.Mos4.HIV
Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.

Biological: Clade C and Mosaic gp140 HIV bivalent vaccine
Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.

Placebo Comparator: Group 2: Placebo
Participants will receive placebo into the deltoid muscle on Months 0 (Day 1), 3 (1 injection), 6 and 12 (2 injections).
Biological: Placebo
Participants will receive matching placebo.




Primary Outcome Measures :
  1. Vaccine Efficacy (VE) as Derived From Confirmed HIV-1 Infections Diagnosed Between the Month 7 and Month X (with 24 Less Than or Equal to [<=] X <= 30) Visits [ Time Frame: From Month 7 up to Month 30 ]
    Vaccine efficacy is defined as 1-cumulative incidence ratio (vaccine versus placebo) between Month 7 and Month X after first vaccination and is estimated by the transformation of the Nelson-Aalen estimator for the cumulative hazard function after enrollment in the per-protocol (PP) population. Here, month X will be between month 24 and month 30.


Secondary Outcome Measures :
  1. Number of Participants with Solicited Local and Systemic Adverse Events (AEs) [ Time Frame: 7 days after each vaccination on Months 0, 3, 6, and 12 ]
    Number of participants with local solicited adverse events will be evaluated. An adverse event is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention, therefore it can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. Solicited local AEs include assessment of pain/tenderness, erythema and swelling. Solicited systemic AEs: fatigue, headache, nausea, myalgia, chills, arthralgia, and vomiting will be assessed.

  2. Number of Participants with Unsolicited Adverse Events [ Time Frame: 28 days after each vaccination on Months 0, 3, 6, and 12 ]
    Number of Participants with unsolicited AEs will be evaluated. Unsolicited adverse events are all adverse events for which the participant is specifically not questioned in the participant diary.

  3. Number of Participants with Medically-attended adverse events (MAAEs) [ Time Frame: Up to 43 Months (participants will be followed until the last participant reaches Month 30) ]
    Number of participants with MAAEs will be evaluated. MAAEs are defined as adverse events with medically attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason.

  4. Number of Participants with Serious Adverse Events (SAEs) [ Time Frame: Up to 43 Months (participants will be followed until the last participant reaches Month 30) ]
    Number of participants with SAE will be evaluated. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

  5. Number of Participants who Discontinue from the Study or Vaccination due to Adverse Events [ Time Frame: Up to 43 Months (participants will be followed until the last participant reaches Month 30) ]
    Number of participants who discontinue from the study or vaccination due to AEs will be evaluated. Participants will be withdrawn from study vaccine administration due to unblinding due to safety reasons, Pregnancy, Confirmed HIV-1 infection, Any related adverse event, Worsening of health status or intercurrent illnesses that in the opinion of the investigator, Required discontinuation from study vaccine, Anaphylactic reaction following vaccination, Serious adverse event or other potentially life-threatening (Grade 4) event that is determined to be related to study vaccine, Chronic or recurrent use of systemic immunomodulators/suppressants, example, cancer chemotherapeutic agents (after discussion with the sponsor), Use of HIV-related monoclonal antibodies (mAbs).

  6. Vaccine Efficacy as Derived From Confirmed HIV-1 Infections Diagnosed at VE (0-X months) per Modified Intent-to-Treat (mITT) Population [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    Vaccine efficacy is defined as 1-cumulative incidence ratio (vaccine versus placebo) between Month 0 and Month X after first vaccination and is estimated by the transformation of the Nelson-Aalen estimator for the cumulative hazard function per mITT populations. Here, month X will be between month 24 and month 30.

  7. Vaccine Efficacy as Derived From Confirmed HIV-1 Infections Diagnosed at VE (13-X months) per mITT Population [ Time Frame: Month 13 up to Month 30 ]
    Vaccine efficacy is defined as 1-cumulative incidence ratio (vaccine versus placebo) between Month 13 and Month X after first vaccination and is estimated by the transformation of the Nelson-Aalen estimator for the cumulative hazard function per mITT populations. Here, month X will be between month 24 and month 30.

  8. Frequency of HIV-1 Env-Specific Humoral Immune Responses as Determined by Clade C gp140 and Mos1 gp140 Specific ELISA [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    Frequency of HIV-1 Env-specific humoral immune responses in PP population will be determined by Clade C gp140 and Mos1 gp140 specific enzyme-linked immunosorbent assay (ELISA).

  9. Frequency of HIV-1 Env-Specific Cellular Immune Responses as Determined by Clinical Potential T Cell Epitopes Envelope Peptide Enzyme-Linked Immunospot [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    Frequency of HIV-1 Env-specific cellular immune responses in PP population will be determined by clinical potential T cell epitopes (cPTE) envelope (Env) peptide enzyme-linked immunospot (ELISpot).

  10. Magnitude of HIV-1 Env-Specific Humoral Immune Responses as Determined by Clade C gp140 and Mos1 gp140 specific ELISA [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    Magnitude of HIV-1 Env-specific humoral immune responses in PP population will be determined by Clade C gp140 and Mos1 gp140 specific ELISA.

  11. Magnitude of HIV-1 Env-Specific Cellular Immune Responses as Determined by cPTE Env peptide ELISpot [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    Magnitude of HIV-1 Env-specific cellular immune responses in PP population will be determined by cPTE Env peptide ELISpot.

  12. Vaccine Efficacy Assessed by Demographic Characteristics [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    The vaccine efficacy assessed by demographic characteristics diagnosed by HIV-1 infection will be reported.

  13. Number of Participants who are Ad26 Seropositive [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    Number of participants who are Ad26 seropositive will be assessed by vector neutralization assay.

  14. Antibody Titers for Ad26 as Determined by Vector Neutralization Assay [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    Antibody titers will be determined by vector neutralization assay.

  15. Sexual Risk Behavior as Assessed by Sexual Activity Questionnaire [ Time Frame: Month 0 (Day 1) up to Month 30 ]
    Sexual risk behavior collected through sexual activity questionnaire (composed with 36 questions) in which participants will be asked about specific sexual activities.

  16. Pre-Exposure Prophylaxis (PrEP) Uptake as Measured by Self Report Questionnaire [ Time Frame: Month 0 (Day 1), 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 and every 3 months post month 30 (up to 48 months) ]
    For HIV-negative participants, participants will be asked whether they use HIV PrEP as part of a self-report questionnaire (composed of 5 questions).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Cis-gender men and transgender individuals who have sex with cis-gender men and/or transgender Individuals.
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Individual is either cis-gender man having sex with cis-gender men and/or transgender individuals or transgender woman having sex with cis-gender men and/or transgender individuals or transgender man having sex with cis-gender men and/or transgender women or gender non-conforming individual having receptive anal and/or vaginal condom-less intercourse and who is considered by the site staff to be at increased risk for HIV-1 infection. The potential participants must in the last 6 months have had any condom-less receptive anal or vaginal sex (not included is condom-less anal sex within a mutually monogamous relationship >=12 months if the partner is HIV negative or living with HIV and virally suppressed) or rectal or urethral gonorrhea or chlamydia or incident syphilis or any stimulant use (example, cocaine, amphetamine) or 5 or more sex partners
  • Potential participant is negative for HIV-1 and HIV-2 infection less than (<) 28 days prior to first vaccination
  • Potential participant must be healthy based on medical history, physical examination, and vital sign measurement performed at screening
  • Contraceptive use by participants assigned female at birth and who have not had sexual reassignment surgery should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies
  • All participants of childbearing potential must have a negative highly sensitive urine or serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and have a negative urine beta-hCG pregnancy test immediately prior to each study vaccine administration

Exclusion Criteria:

  • Potential participants choosing to use PrEP. However, once participants received the first vaccination, they will be allowed to start PrEP while in the study according to the site PrEP plan. The use of long acting PrEP is disallowed from 24 months prior to Day 1
  • Potential participant is a recipient of a HIV-vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months prior to Day 1. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months prior to Day 1, documentation of the identity of the experimental vaccine must be provided to the HPX3002/HVTN 706 safety review team, who will determine eligibility on a case by-case basis
  • Potential participant has received an HIV-related mAb, whether licensed or investigational, within the last 12 months prior to Day 1. For participants who received an HIV-related mAb more than 12 months prior to Day 1, documentation of the identity of the mAb must be provided to the HPX3002/HVTN 706 safety review team, who will determine eligibility on a case-by-case basis
  • Potential participant has known allergy or history of anaphylaxis or other serious adverse reactions to vaccines
  • Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study vaccination

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03964415


Contacts
Layout table for location contacts
Contact: Study Contact 844-434-4210 JNJ.CT@sylogent.com

  Show 57 Study Locations
Sponsors and Collaborators
Janssen Vaccines & Prevention B.V.
Investigators
Layout table for investigator information
Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial Janssen Vaccines & Prevention B.V.

Layout table for additonal information
Responsible Party: Janssen Vaccines & Prevention B.V.
ClinicalTrials.gov Identifier: NCT03964415     History of Changes
Other Study ID Numbers: CR108604
2018-003666-13 ( EudraCT Number )
VAC89220HPX3002 ( Other Identifier: Janssen Vaccines & Prevention B.V. )
HVTN 706 ( Other Identifier: HIV Vaccine Trials Network (HVTN) )
First Posted: May 27, 2019    Key Record Dates
Last Update Posted: August 7, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

URL: https://www.janssen.com/clinical-trials/transparency

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Vaccines
Immunologic Factors
Physiological Effects of Drugs